Versantis’ pipeline starts with strong science and aims to improve patients’ outcome and potentially relieve health care systems from the economic burden of liver diseases.
Our lead program, VS-01-ACLF, is Phase 2a-ready following clinical trial application approval from The Federal Institute for Drugs and Medical Devices (BfArM) in Germany. This product candidate leverages our proprietary scavenging liposomes technology to potentially reverse the multi-organ complications arising from acute-on-chronic liver failure in patients with advanced liver cirrhosis. It is being developed for two acute indications, both of which are rare diseases associated with high unmet medical needs.
Versantis’ discovery programs aim to widen the company’s footprint in liver diseases and provide a continuum of care from that targeted point-of-care, diagnostic test kit of ammonia levels in blood (TS-01) to the potential treatment of hepatic encephalopathy (VS-02).
TS-01 is a unique point-of-care diagnostic device in prototype development for the at-home measurement of ammonia in blood, the primary cause of HE. It has the potential to provide HE patients with an instrument to manage tighter control of their blood-ammonia levels and provide a means to better manage companion therapeutic treatments for their condition.